Sanofi (France)'s CEO on Surviving Patent Cliff, Drug Prices
Published: Oct 29, 2012
Yesterday, I had the chance to sit down with Christopher Viehbacher, who has been the chief executive of Sanofi, the fourth-largest drug company in the world, since 2008. A video of the first part of our conversation is embedded in this post. Viehbacher has worked hard to stablize Sanofi, a proud French company, as it has faced the expiration of the patents on many of its biggest drugs: best-sellers like Plavix for heart disease and Eloxatin and Taxotere for cancer. Now the company is emerging from the patent cliff with the long-acting-insulin, Lantus, leading the way.